thank stand welcome laboratory first quarter earn conference call operator instruction operator instruction would like hand conference speaker today vice president investor relation thank please ahead corporate vice president investor relation thank good morning welcome laboratory first quarter earn conference call webcast morning foster chairman president chief executive officer executive vice president chief financial officer comment result first quarter follow presentation respond question slide presentation associate today remark post investor relation section website criver webcast replay call available begin hour today call also access investor relation website replay available next quarter conference call like remind safe harbor remark make future expectation plan prospect company constitute forward look statement private security litigation reform actual result differ materially indicate call primarily financial measure believe help investor gain meaningful understand core operate result guidance financial measure mean consider superior substitute result operation prepare accordance accordance regulation find comparable measure reconciliation investor relation section website turn call foster foster chairman president chief executive officer good morning please speak today another exceptional quarter robust first quarter financial performance highlight organic revenue growth basis point year year operate margin improvement demonstrate strength biopharmaceutical market environment power unique portfolio believe strong ever believe client increasingly choose partner flexible efficient outsource solution scientific depth breadth portfolio unwavering focus seamlessly serve diverse need client work smaller number offer broader scientific capability enable drive greater efficiency accelerate speed research nonclinical development manufacture program complexity scientific research also increase client reliance high science outsource partner like differentiate competition strategically expand portfolio area deliver greatest value client offer significant growth potential already year enhance scientific capability advance drug modality acquisition distribute distribute strengthen discovery portfolio acquisition complete march provide excellent growth opportunity allow offer service high growth high science cell gene therapy sector please welcome talented staff organization believe continue invest portfolio people maintain enhance position lead nonclinical believe strength portfolio robust industry fundamental lead unprecedented client demand across business first quarter experience continuation robust demand last year include record book proposal level safety assessment business organic revenue second consecutive quarter even normalize last year impact overall believe robust first quarter performance solid business trend support improve outlook year provide highlight first quarter performance quarterly revenue surpass million first time million first quarter represent increase last year organic revenue growth drive double digit growth across three segment year year comparison last year relate revenue impact primarily affect segment contribute approximately basis point revenue growth rate quarter experience broad base growth across client segment biotech client lead continue benefit robust fund environment operate margin increase basis point year year improvement drive segment reflect operate leverage robust revenue growth continue effort drive efficiency expect factor drive margin improvement year believe operate margin approach prior target earn share first quarter increase first quarter last year outstanding earn growth principally reflect double digit revenue growth meaningful operate margin improvement base first quarter performance positive outlook remainder year meaningfully increase revenue growth earn share guidance expect organic revenue growth range basis point increase prior range normalize last year impact would still expect double digit organic revenue growth year earn share expect represent year year growth increase midpoint prior outlook like provide detail first quarter segment performance begin segment revenue million first quarter increase organic basis first quarter drive broad base demand discovery safety assessment safety assessment business continue perform exceptionally reflect robust demand biotech global biopharma client price increase book proposal volume reach record high first quarter strength across region major service area book increase substantially target client expand preclinical pipeline intensify focus complex biologics believe secure space advance ensure delay research turn provide greater visibility believe position safety assessment business extremely support double digit organic revenue growth segment year higher prior outlook please extensive depth breadth safety assessment portfolio remain intently focus continue enhance value provide client discovery business another exceptional quarter lead broad base demand oncology early discovery service effort broaden strengthen discovery capability enhance scientific expertise enable expand support provide client discovery research client increasingly view premier scientific partner support effort identify drug target discover novel therapeutic intend build discovery portfolio client outsource complex discovery project include advance modality recent acquisition distribute enhance large molecule discovery capability proprietary cell technology offer target receptor identification target screen service enhance client early discovery effort also enable explore potential preclinical safety liability combination distribute large molecule discovery platform capability strengthen integrate solution therapeutic antibody cell gene therapy discovery development also continue edge technology strategic partnership strategy recently artificial intelligence drug discovery partner discovery operate margin increase basis point first quarter leverage robust revenue growth primary driver margin improvement expect trend continue propel margin range year revenue million increase organic basis first quarter robust demand research model primary driver first quarter revenue growth higher revenue research model service include initiative also contribute approximately basis point increase attributable comparison last year relate revenue impact client site closure disruption demand trend research model largely consistent prior pandemic growth widely outpace mature market research model business exceptional quarter even normalize last year impact drive resurgence demand across segment biomedical research return level area even greater level client order activity also rebound research model service also continue perform benefit renew outsource demand client seek greater flexibility efficiency afford manage proprietary model many client pandemic addition complex research model play increasingly critical role drug research continue shift oncology rare disease cell gene therapy reinforce value proposition business also continue generate substantial client interest initiative accelerator development small large biopharmaceutical client increasingly seek turnkey research capacity allow invest people research instead infrastructure site area south biohubs actively expand region accommodate client demand utilize also provide client collaborative opportunity seamlessly access service discovery enhance speed efficiency research program revenue growth cell supply business remain target level first quarter limitation donor access believe cell supply revenue increase year donor availability continue improve also continue work diligently expand donor base comprehensive capability site accommodate robust demand broader cell therapy market believe acquisition particularly time timely create business opportunity cell gene therapy development area expand capability expand establish trust partner move client program forward cellular product step research early stage development phase production first quarter operate margin increase basis point significant improvement factor first last year margin depress onset relate client disruption result impact research model order activity addition year performance reflect operate leverage attributable robust revenue growth particularly research model revenue manufacture segment million increase organic basis first quarter last year increase drive double digit revenue growth biologics test solution microbial solution business manufacture segment first quarter operate margin stable consistent historical trend first quarter line revise expectation operate margin factor acquisition microbial solution growth rate rebound level first quarter reflect strong demand endotoxin test system cartridge core reagent geographic region continue work delay instrument installation result restriction gain access client site please strength underlie demand endotoxin test platform perform mandate release test client critical quality control test need client prefer comprehensive efficient microbial test solution quality speed accuracy test platform biologics business report another exceptional quarter strong double digit revenue growth principally drive robust market demand test cell gene therapy therapeutic believe cell gene therapy continue significant growth driver year come demand vaccine test intensify therapy move commercial production phase even early stage test activity subside give strength demand environment continue build extensive portfolio service support safe manufacture biologics ensure available capacity accommodate client demand believe acquisition highly complementary biologics business portfolio whole acquisition establish premier scientific partner cell gene therapy development test manufacture broader service provide client integrate solution basic research production enable outsource cell therapy production require analytical test scientific partner reduce bottleneck efficiency utilize multiple outsource provider already provider extensive nonclinical service cell gene therapy integration process proceed smoothly particularly focus unlock business opportunity across portfolio acquisition part ongoing strategy broaden unique portfolio scientific expertise order support paradigm therapeutic area research biopharmaceutical client seek drive greater efficiency leverage scientific benefit work fewer trust partner broad integrate capability transform business last decade accommodate need scientific partnership internal investment promote culture continuous improvement everything build lead safety assessment franchise world establish integrate discovery offer small large molecule give emerge importance complex biologics cell gene therapy capability logical extension portfolio continue move growth strategy forward discipline strategic partnership remain vital component strategy endeavor enhance scientific expertise global reach innovative technology offer client across three business segment invest scientific capability internally necessary staff resource help ensure meet need client support robust growth market biotech fund environment never stronger client invest research development incumbent upon scientific partner help move program forward concept nonclinical development safe manufacture life segment therapeutic look forward discuss strategy think take company next several year upcoming virtual investor conclusion like thank client shareholder support employee exceptional work commitment give additional detail first quarter result guidance corporate executive vice president chief financial officer good morning begin remind speak primarily result exclude amortization acquisition relate charge relate primarily global efficiency initiative venture capital strategic investment performance certain item many comment also refer organic revenue growth exclude impact acquisition foreign currency translation please accomplishment first quarter widely outperform outlook deliver strong revenue growth level organic basis significant operate margin expansion basis point drive earn share growth operate margin performance particularly encourage consistent margin improvement reflect effort build scalable efficient infrastructure leverage robust growth market mention increase year financial guidance reflect enhance growth profile full year include strong performance first quarter addition acquisition complete expect deliver report revenue growth organic revenue growth range full year give robust line performance expect drive meaningful operate margin improvement year full year margin approach expect drive better expect earn share range represent year year growth segment outlook continue reflect strong business environment differentiate capability provide support client need organic revenue growth guidance year unchanged initial high teen outlook reflect recovery impact pandemic last year exceptional growth expectation cell supply revenue growth improve year segment expect deliver double digit growth full year reflect strong first quarter performance intensify early stage research activity manufacture segment expect achieve teen organic revenue growth biologics microbial solution business contribute include acquisition manufacture report revenue growth rate expect high range regard operate margin continue primary contributor overall improvement year segment margin meaningfully also expect segment operate margin increase prior year range factor manufacture segment operate margin expect range year moderately level unallocated corporate slightly higher expectation total total revenue million first quarter compare revenue first quarter last year increase primarily result continue investment support growth business higher performance base compensation part first quarter operate outperformance despite higher expense first quarter continue expect unallocated corporate range percentage revenue full year first quarter rate basis point increase year year consistent outlook call rate teen gate excess benefit stock base compensation continue expect full year rate range basis unchanged outlook provide total adjust interest expense first quarter million essentially flat sequentially decrease nearly million year year lower average debt level result interest rate save base leverage ratio first quarter billion outstanding debt represent gross leverage ratio time leverage ratio time march issue billion senior note optimize capital structure take advantage attractive interest rate environment proceed bond offer redeem previously issue higher rate million bond exist term loan portion revolve credit facility finance portion acquisition also amend exist credit agreement establish revolver borrow capacity billion result action reduce average interest rate debt approximately basis point overview current capital structure provide slide forma basis include acquisition gross leverage ratio three time total debt outstanding slightly billion year higher debt balance primarily acquisition partially offset lower average interest rate refinance activity expect result total adjust interest expense million million free cash flow million first quarter significant increase compare million last year primary reason improvement strong first quarter operate performance along continue focus work capital management capital expenditure million first quarter compare million last year look ahead increase capex guidance million approximately million increase primarily reflect investment make support high growth business even additional capital expect capex remain total revenue year consistent target provide last investor full year update free cash flow guidance upper prior range expect free cash flow approximately million full year please able increase free cash flow primarily strong first quarter operate performance even incorporate transaction capital need summary revise financial guidance full year include find slide second quarter update outlook reflect continuation strong demand environment expect second quarter report revenue growth near level include contribution organic basis expect second quarter growth rate near reflect prior year comparison relate revenue impact contribute approximately basis point second quarter revenue growth result impact second quarter last year expect year second quarter operate margin earn share increase significantly versus prior year expectation earn share growth rate year year conclusion please strong first quarter performance include robust revenue free cash flow growth remain confident prospect year ability consistently grow line bottom line cash generation believe reflect substantial improvement outlook look forward host upcoming virtual investor week time plan update longer term financial target believe reflect strong demand environment thank corporate vice president investor conclude comment operator take question